UTHR

United Therapeutics Corp. (UTHR) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. United Therapeutics is a biotechnology company focused on developing and commercializing therapies for chronic and life-threatening conditions, primarily pulmonary arterial hypertension (PAH) and neuroblastoma. The company operates as a single reporting segment and is a Delaware public benefit corporation.

Key Financial Metrics

Note: Free Cash Flow calculated as Net Cash from Operating Activities ($463.3M) less Capital Expenditures ($100.8M).

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 2% to $781.5 million. This was driven by a 22% drop in Nebulized Tyvaso sales (due to lower U.S. quantities) and an 8% decline in Remodulin sales. These decreases were partially offset by a 9% increase in Tyvaso DPI sales and a 12% increase in Orenitram sales.
• Cost of Sales Increase: Cost of sales rose 44% to $133.4 million. The primary driver was a $44.9 million inventory reserve expense, including a $26.8 million estimated loss related to a commercial supply agreement for Tyvaso DPI inventory.
• Other Expense Volatility: "Other expense, net" increased significantly to a $46.3 million expense (from a $4.3 million expense in 2025), primarily due to $61.6 million in net unrealized losses on equity securities.
• Share Repurchases: The company executed a $1.5 billion accelerated share repurchase (ASR) program in March 2026, resulting in a significant reduction in cash and treasury stock increases.

Guidance, Outlook, and Risks

• Pipeline Progress:
  • Nebulized Tyvaso (IPF): Announced successful Phase 3 results (TETON-1 and TETON-2 studies) for Idiopathic Pulmonary Fibrosis (IPF). Plans to submit a supplemental NDA (sNDA) by the end of summer 2026.
  • Ralinepag: Announced successful Phase 3 results (ADVANCE OUTCOMES study) for PAH. Plans to submit an NDA by the end of summer 2026.
  • Xenotransplantation: The EXPAND study for the UKidney product is ongoing with the first transplant occurring in Q4 2025. The EXTEND study for UThymoKidney received FDA clearance in August 2025.
• Competition: Liquidia launched Yutrepia in June 2025, competing directly with Tyvaso products. Merck's Winrevair is also a competitor in the PAH space. Generic competition continues to impact Remodulin sales internationally.
• Litigation Risks:
  • Sandoz Litigation: A final judgment ordered the company to pay approximately $61.6 million in damages plus interest. The company has accrued $74.9 million (as of March 31, 2026) and is appealing the decision.
  • Liquidia Litigation: Ongoing patent infringement and trade secret misappropriation lawsuits regarding Yutrepia and Tyvaso DPI. Trial dates are set for 2025 and 2027.
• Capital Allocation: The Board approved a new $2.0 billion share repurchase program in March 2026. Approximately $500 million remains available under this authorization as of March 31, 2026.

Investor Verification Checklist

• Verify the final settlement share count and average price for the $1.5 billion March 2026 Accelerated Share Repurchase (ASR) agreements.
• Monitor the status of the Sandoz appeal and potential adjustments to the accrued $74.9 million litigation liability.
• Track the FDA review timeline for the Nebulized Tyvaso (IPF) and Ralinepag (PAH) NDAs expected in summer 2026.
• Assess the impact of the $26.8 million Tyvaso DPI inventory reserve on future gross margins and supply chain stability.
• Review the progress of the UKidney and UThymoKidney clinical trials and the timeline for Biologics License Application (BLA) submissions.